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Abstract
Background:  The evidence base for improving reproductive health continues to grow. However,
concerns remain that the translation of this evidence into appropriate policies is partial and slow. Little is
known about the factors affecting the use of evidence by policy makers and clinicians, particularly in
developing countries. The objective of this study was to examine the factors that might affect the
translation of randomised controlled trial (RCT) findings into policies and practice in developing countries.
Methods: The recent publication of an important RCT on the use of magnesium sulphate to treat pre-
eclampsia provided an opportunity to explore how research findings might be translated into policy. A
range of research methods, including a survey, group interview and observations with RCT collaborators
and a survey of WHO drug information officers, regulatory officials and obstetricians in 12 countries, were
undertaken to identify barriers and facilitators to knowledge translation.
Results: It proved difficult to obtain reliable data regarding the availability and use of commonly used drugs
in many countries. The perceived barriers to implementing RCT findings regarding the use of magnesium
sulphate for pre-eclampsia include drug licensing and availability; inadequate and poorly implemented
clinical guidelines; and lack of political support for policy change. However, there were significant regional
and national differences in the importance of specific barriers.
Conclusion: The policy changes needed to ensure widespread availability and use of magnesium sulphate
are variable and complex. Difficulties in obtaining information on availability and use are combined with
the wide range of barriers across settings, including a lack of support from policy makers. This makes it
difficult to envisage any single intervention strategy that might be used to promote the uptake of research
findings on magnesium sulphate into policy across the study settings. The publication of important trials
may therefore not have the impacts on health care that researchers hope for.
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Background
Translating research evidence into policy is crucial to
improving the evidence base of health care as well as to
improving health care outcomes. Indeed, the recent Min-
isterial Summit on Health Research in Mexico City noted
that, "Research has a crucial but under-recognised part to
play in strengthening health systems, improving the equi-
table distribution of high quality health services, and
advancing human development." [1]. Other have voiced
similar views [2-4]. However, knowledge regarding both
the factors affecting the use of evidence by policy makers
and the effectiveness of interventions to improve the use
of evidence by policy makers remains underdeveloped
[5,6]. While some studies have been undertaken in devel-
oping countries [7,8], knowledge from these settings is
particularly thin. For example, a recent systematic review
of interview studies and surveys of health policy makers'
perceptions of their use of evidence found 24 eligible
studies, of which only four were conducted in low and
middle income country settings [5]. Further studies of
research-policy linkages in developing countries could
therefore be helpful.
A number of models have been suggested to explain the
role of research in policy making [9-13]. In summary, the
models include so-called 'rational' approaches in which
the uptake of research findings into policy making is
envisaged as a linear process, with research-based knowl-
edge promoting policy change and practice. Alternative
approaches view the research-policy relationship as one of
'enlightenment' suggesting, in contrast to the linear mod-
els, that research findings 'percolate' through the policy
environment, gradually influencing ideas and
approaches. These approaches suggest a more complex
and contested relationship between research and policy
making, with research being one of many knowledge
sources used by policy makers in taking decisions. Others
have focused on the networks of influence and 'policy
communities' – including civil servants, civil society
organisations and others – that may form around, and
influence, specific issues. It has also been suggested that
research may be used strategically to delay or support pol-
icy decisions. We return to these models later in discussing
the study results.
In this paper, we report the findings of a study that exam-
ined, firstly, the factors perceived as limiting the use of the
results of a recently published trial of magnesium sul-
phate for the treatment of pre-eclampsia and, secondly,
the extent to which it might be possible to make general-
isable inferences regarding barriers to and facilitators of
evidence-based pharmaceutical policies for maternal and
child health.
Eclampsia is an important contributor to maternal mor-
bidity and mortality in low-income countries [14].
Eclampsia is the occurrence of a convulsion (fit) in associ-
ation with pre-eclampsia. Pre-eclampsia has been defined
as "a multisystem disorder [of pregnancy] that is usually
associated with raised blood pressure and proteinuria but,
when severe, can involve the woman's liver, kidneys, clot-
ting system, or brain. The placenta is also often involved,
with an increased risk of poor growth and early delivery
for the baby." [15] An estimated 50,000 women die annu-
ally following eclamptic convulsions and 99% of these
deaths occur in low and middle income countries [16].
Strong evidence of the effectiveness of magnesium sul-
phate for women with eclampsia has been available since
1995 [15,17,18]. Until recently, however, there was little
reliable evidence regarding the effectiveness of magne-
sium sulphate for preventing the onset of eclampsia for
women with pre-eclampsia. The results of the Magpie
(MAGnesium sulphate for Prevention of Eclampsia) Trial,
published in 2002, provide convincing evidence that
magnesium sulphate is also effective for prevention of
eclampsia [19,20]. Given this evidence, there is concern
that this effective, safe and inexpensive drug may still not
be available in many countries for women with eclampsia
or pre-eclampsia [21,22]. Hundreds of thousands of
women could benefit from these research results, pro-
vided they are translated into appropriate policies and
practice. Given these concerns, this study examined fac-
tors that might hinder or facilitate the translation of the
results of the Magpie Trial into appropriate policies and
practice. We also discuss what might be done at interna-
tional level by researchers, the WHO and other interna-
tional agencies to address these.
Methods
A case study approach, that involves examining a natu-
rally occurring case or cases, was used to explore the
research questions [23]. The selected case – in this
instance how the findings of the Magpie Trial might be
translated into policy in developing countries – was
viewed as a whole, allowing processes to be compared and
explored [24,25]. As such, we did not aim to investigate
the fine detail of specific elements of the research transla-
tion process in each setting, but rather attempted to
assemble a broad overview of the research-policy interface
for the research finding of interest. For the purposes of this
study, we understood 'policy' to include both service pol-
icies, which relate to resource allocation and the organisa-
tion of services, and practice policies, which are concerned
with the use of resources by clinicians involved in deliver-
ing health care ([26]).
Data were collected in two phases using a range of com-
plementary qualitative and quantitative methods. Firstly,
we conducted observations, a semi-structured group inter-BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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view and a survey of members of the Magpie Trial Collab-
orative Group – a research team representing 33 countries
and involved in the Magpie Trial. Secondly, we conducted
a survey of drug information officers in twelve developing
countries. The details of these methods are described
below.
Phase 1: perceptions of the Magpie Trial collaborative 
group
A meeting of the Magpie Trial collaborators in March
2002 to discuss the trial findings prior to publication pro-
vided an opportunity to explore the perceptions of this
group, with a strong interest in developing the evidence
based for obstetric care, regarding the barriers and facilita-
tors to implementing the findings of their study. Limited
time was available during this meeting for data collection.
However, we saw this opportunity as important since
most of the trial collaborating centres were represented.
Several data collection methods were used, as described
below.
Observations
Small group and plenary discussions on the dissemina-
tion and implementation of the trial results were observed
during the Magpie Trial meeting. The collaborators
planned these independently of our study. The groups
were organised by geographical regions: Africa, Asia, Latin
America, and a fourth group that included European,
North American and Australian collaborators. Notes of
the discussions were made.
Group interview
A brief semi-structured group discussion was conducted
with six collaborators from Brazil, Egypt, Pakistan and
Uganda, purposively selected to represent a variety of
developing countries. This focused on the implications of
the possible Magpie Trial results and strategies for dissem-
ination and implementation. Detailed notes of the inter-
view were taken and the data from the interview and the
observations were coded and subjected to thematic analy-
sis. The issues that emerged were used to help interpret the
survey results.
Survey of the Magpie Trial collaborative group
A questionnaire was designed to explore barriers and facil-
itators to the uptake of the Magpie Trial findings into
national, regional and hospital level policies in the
respondent's country. A mix of open- and closed-ended
questions addressed current policies regarding magne-
sium sulphate, specific barriers and facilitators and neces-
sary changes in policies. It also attempted to identify key
policy makers. The questionnaire was distributed after
presentation of the Magpie Trial results. Spanish speaking
participants were given the option of answering the open-
ended questions in Spanish. These responses were later
translated into English. MA and SI independently coded
and qualitatively analysed the responses to the open
ended questions. Other data were entered into an Excel
database for analysis.
Phase 2: Survey of national drug information officers
Following analysis of Phase 1 data, a pilot survey of
national drug information officers in twelve low and
lower-middle income countries (Albania, Armenia,
Bolivia, Cambodia, India, Indonesia, Iran, Nicaragua, the
Philippines, Rwanda, South Africa, and Yemen) was con-
ducted. The survey had the following objectives: to
explore the generalisability of the perceptions of the Mag-
pie Trial Collaborative Group; to collect data for countries
that had not participated in the Magpie Trial (Armenia,
Bolivia, Cambodia, Indonesia, Iran, Nicaragua, Philip-
pines, Rwanda); to overcome some of the limitations of
the information collected from the collaborators; to
explore the feasibility of a survey approach for collecting
data from a larger sample of countries; and to assess the
reliability of the information gathered. The countries were
purposively selected to represent geographic, cultural and
political variety.
Drug information officers were identified through the
World Health Organisation (WHO) Department of Essen-
tial Drugs and Medicines. We attempted to validate the
information provided by drug information officers
through surveying obstetricians in each country. These
were identified by personal contacts. The questionnaire
for drug information officers focused on the registration,
supply and distribution of magnesium sulphate. Informa-
tion was also sought on five other drugs: folic acid to pre-
vent anaemia and the risk of fetal malformation,
ergometrin to decrease post partum haemorrhage, oxy-
tocin to induce labour, hydralazine to treat hypertension
during pregnancy, and nevirapine to prevent mother-to-
child transmission of HIV [27]. The first three of these are
similar to magnesium sulphate in that they are inexpen-
sive, have been used for many years, and indications for
their use are common. Hydralazine was selected because
it was being considered for removal from the model
essential medicines list. Nevarapine was selected because
it was expensive and relatively new. The questionnaire for
obstetricians focused on the availability and use of mag-
nesium sulphate. Both questionnaires consisted of closed-
ended questions with space for comments. Data were
entered into an Excel database and analysed using simple
descriptive statistics.
Results
Group interview and observations – Magpie Trial 
collaborators
The group interview and observations identified a number
of issues seen by Magpie collaborators as barriers to trans-BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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lating the Magpie Trial results into appropriate policies
and practice. In presenting these, we have utilised the pol-
icy analysis framework of actors, context, content and
process as an organising scheme [28]. With regard to con-
text, a range of problems with the availability of magne-
sium sulphate across the trial settings was discussed. The
drug was reported to be available in Latin America, Bang-
ladesh and to some extent in India. In Pakistan and
Uganda, however, magnesium sulphate was not registered
as a pharmaceutical and respondents noted that there was
controversy over whether it should be included in the
essential medicines list. Access was also seen as a problem
in Zimbabwe as the drug had not been registered even
though it was listed on the essential medicines list. One
participant commented that magnesium sulphate "is so
cheap that the pharmaceutical companies don't bother to
push for its registration", indicating one reason for the
failure to register the drug in some settings. In contrast,
access to magnesium sulphate was not considered to be a
problem in high income settings and very frequent use
was identified as a problem in parts of Latin America.
There was a range of views regarding the potential for local
manufacture of magnesium sulphate – a route seen as
potentially useful in ensuring a low cost supply of the
drug. Other problems raised included inequalities in
availability between government and private hospitals
and patient level barriers to improving attendance for
antenatal care, including cost, transportation, traditions
and beliefs. It was suggested that policy makers and poli-
ticians needed to be brought "on board" with health care
professionals to address these issues.
A number of actors were identified as important to the
research translation process. The collaborators suggested
that few clinicians or policy makers in their settings were
aware of the concept of evidence-based medicine, would
read the Magpie Trial report or be able to interpret the
findings. Even if clinicians were aware of the Magpie Trial
results, few had opportunities to influence relevant poli-
cies. Collaborators from West Africa felt that there was a
need, through medical associations, to involve politicians
at the national level in discussing the trial findings. Such
policy makers were seen to be distant from poor and
under-resourced areas of the country, further exacerbating
barriers to the development and application of appropri-
ate policies for these areas. Collaborators from high
income countries also thought that professional organisa-
tions would be important in drawing out the implications
of the trial findings and making clear recommendations.
The collaborators held differing views about the impor-
tance of support from WHO and the United Nations Chil-
dren's Fund (UNICEF) in influencing policies and
practice. For example, collaborators from Nigeria consid-
ered it important to get support from the WHO region as
this office had close relations with policy makers and pol-
iticians. One collaborator in the Asian group argued that
if WHO provided magnesium sulphate to health facilities
at no cost for one year, this would create pressure on gov-
ernments and pharmaceutical companies to continue
supplying it thereafter. In at least one of the countries rep-
resented in the discussion, UNICEF was attempting to
implement protocols for emergency obstetrical care and
was therefore seen as having as import role in policy mak-
ing. The influence of international agencies, such as WHO
and UNICEF, on the mass media was also highlighted.
A range of problems with the process of developing and
implementating clinical guidelines for the treatment of
hypertensive disorders of pregnancy was raised. Some
countries had no national guidelines and institutions
were not under any obligation to follow recommended
procedures. Consequently, each hospital followed its own
policies. Elsewhere national guidelines existed, but mag-
nesium sulphate was used routinely only for eclampsia
and not for pre-eclampsia. Furthermore, even where mag-
nesium sulphate was widely available, appropriate hospi-
tal facilities, such as intensive care units, were seen as
necessary to implementing the Magpie Trial results due to
the perceived need for close monitoring of patients. Sev-
eral participants suggested that an active guideline imple-
mentation process was required at each hospital. For
example, in South Africa, where national policy recom-
mended the use magnesium sulphate for eclampsia, the
main problem was considered to be training for health
professionals. Training was also seen as important in the
Asian countries. However, it was acknowledged that this
would require substantial resources.
The content and focus of the policy implementation proc-
ess was also seen as important and to require tailoring to
specific settings. In Latin America one of the important
issues identified was the very frequent use, rather than the
underuse, of magnesium sulphate. Here, it was suggested,
training and implementation needed to focus on raising
awareness of the lack of evidence to support giving mag-
nesium sulphate to women with relatively mild disease. A
lack of accountability of obstetricians was also considered
to be a key problem in several settings. It was suggested
that legislation was needed to specify standards of, and
responsibilities for care.
A number of dissemination and implementation strate-
gies for translating the Magpie Trial findings were sug-
gested. The African group considered it important for the
researchers themselves to publish articles in a variety of
national and regional medical journals to gain support for
developing and implementing appropriate guidelines.
Some participants felt that the mass media could play a
role in advocating for the registration of magnesium sul-BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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phate, but there were perceived problems with the quality
of health care reporting and a need for health care profes-
sionals to work closely with journalists. It was also noted
that many journalists were based in well resourced central
urban areas and did not reflect the views of more poorly
resourced peripheral regions.
In summary, significant regional and national differences
in the policy making context were identified, including
the importance of clinical guidelines and availability of
and access to magnesium sulphate. The role and influence
of different policy actors, including international agencies
and the media, was also seen to vary between settings, as
did the barriers to the process of developing and imple-
menting evidence based policies.
Survey of the Magpie Trial collaborative group
A response rate of 81% (89/110 participants) was
achieved. Some questions were not answered by some
respondents and other responses were illegible. Table 1
shows the countries represented by the 89 respondents.
The distribution reflects that of the Magpie Trial partici-
pants, with half of the respondents coming from just three
countries – South Africa, Argentina and the United King-
dom – from where half of trial participants were recruited
[19]. Sixty-five (73%) of the respondents were obstetri-
cians. There were twelve "other" physicians, five mid-
wives, two researchers, two health managers and three
respondents who did not state their profession. Based on
World Bank country classifications [29], 39 (44%) of the
respondents represented 13 low or lower-middle income
countries, 20 (22%) represented 3 upper-middle income
countries, 24 (27%) represented 8 high-income countries
and 6 (7%) did not state which country they represented.
Table 2 shows the main barriers identified by respondents
to the dissemination and implementation of the Magpie
Trial results. Respondents from low and lower-middle
income countries most frequently identified "political
barriers" as a factor that might hinder the dissemination
and implementation of the trial results (8/13 countries
including 13/39 respondents). Issues cited by these
respondents included lack of political will; that policy
makers were poorly informed of, and insufficiently
involved in, these matters; and that they did not see pre-
eclampsia as a priority health problem. Public authorities
were also identified as a barrier (4/13 countries including
6/39 respondents). In addition, lack of availability of the
drug and of appropriate health personnel for its adminis-
tration, as well as costs, were frequently raised. Respond-
ents from two of the three upper-middle income countries
(Argentina, Brazil and Mexico) highlighted political barri-
ers (5/20 respondents) such as a lack of political engage-
ment, lack of information or awareness (5/20
respondents), and costs (4/20 respondents) as important
obstacles. A number of respondents from high-income
countries indicated that applying the results of the Magpie
Trial was not an important issue in their setting.
Table 3 shows factors identified by respondents as having
the potential to facilitate dissemination and implementa-
tion of the Magpie Trial results. In low and lower-middle
income countries as well as upper middle-income coun-
tries, the most frequently mentioned facilitator was estab-
lishing channels to public authorities (6/13 and 2/3
countries respectively). In addition, clinical practice
guidelines, resources and international organisations
were seen as playing an important role in low and lower-
middle income countries. Professional organisations were
seen as important in upper middle-income countries (3/3
countries). The most frequently mentioned facilitator for
the high-income countries was clinical practice guidelines
(4/8 countries). In general, the facilitators identified
addressed the barriers highlighted by the respondents.
Table 1: Geographical distribution of the respondents to the 
Magpie Trial Collaborative Group survey
Region Country Number of 
respondents
Africa 27
South Africa 13
Nigeria 6
Uganda 3
Egypt 1
Ghana 1
Malawi 1
Sierra Leone 1
Zimbabwe 1
Latin America 20
Argentina 16
Brazil 2
Mexico 2
Asia 13
India 5
Pakistan 3
Bangladesh 2
Singapore 1
UAE 1
Yemen 1
Europe 19
UK 16
Albania 1
Italy 1
Netherlands 1
North America 2
Canada 1
USA 1
Australia Australia 2
Not stated 6
Total 24 89BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
Page 6 of 13
(page number not for citation purposes)
Representatives from 7/13 low and lower-middle income
countries and 2/8 high-income countries reported that
magnesium sulphate was not licensed for the treatment of
pre-eclampsia (not shown in tables). This barrier was not
raised by respondents in upper-middle income countries.
However, there were frequently conflicting responses to
this question by respondents from same country. Reasons
why magnesium sulphate was not licensed included fail-
ure to submit an application for licensing and "red tape".
In each of 4/13 low and lower-middle income countries,
one or more respondents said that magnesium sulphate
was not available. Distribution of magnesium sulphate
was reported to be a problem by at least one respondent
from 8/13 low and lower-middle income countries and 1/
3 upper-middle income countries.
Respondents indicated that there were no national clinical
practice guidelines for pre-eclampsia in 8/13 low and
lower-middle income countries and 2/8 high-income
countries. Local (hospital) guidelines were available in
most settings (82% of respondents). However, only half
of respondents considered the recommendations in local
guidelines to be appropriate in light of the Magpie Trial
results.
Contextual health system factors were identified by
respondents as important in determining the uptake of
the trial findings into policy. At least one respondent in
13/16 low and middle income countries noted that fewer
than 60% of pregnant women had access to services where
pre-eclampsia was likely to be appropriately diagnosed.
Furthermore, fewer than 40% of pregnant woman had
access to professionals who could administer magnesium
sulphate, according to at least one respondent in 10/13
low and lower-middle income countries. The costs of
magnesium sulphate and hospital care were thought
likely to hinder the dissemination and implementation of
the Magpie Trial results in six of these countries. However,
there were frequently different responses to this question
from representatives of the same country. At least one
respondent from ten of the thirteen low and lower-middle
income countries thought that costs were not a barrier.
Most of the respondents from low and lower-middle
income countries considered it important to change poli-
cies in their countries to improve the availability (median
importance score of 5.0 on a scale from 1 [not important]
to 5 [very important]) and distribution of magnesium sul-
phate (median importance score = 5.0). Improving access
to hospitals offering treatment with magnesium sulphate
and to professionals trained to manage pre-eclampsia
were also seen as important (median importance scores =
5.0 and 5.0 respectively). Respondents from upper-mid-
dle income countries saw changes in policies to improve
the availability of the drug as less important (median
score = 2.5). The other three issues (drug distribution,
access to hospitals and access to trained professionals)
were seen as important by these respondents (median
importance scores = 4.0, 4.0 and 5.0). For high income
countries, however, all four of these issues were perceived
to be less crucial (median importance scores = 1.0, 1.0, 1.0
and 2.0). Changes in clinical practice guidelines were seen
as necessary in low and high-income countries (median
importance 5.0 and 4.8 respectively), but less so in upper-
middle income countries (median importance 3.5).
Changes in policies regarding payment for magnesium
sulphate and hospital costs were considered more impor-
tant in low and lower-middle income countries (median
importance 5.0 and 5.0 respectively) than in upper-mid-
dle income countries (median importance 2.0 and 4.0)
Table 2: Barriers to the dissemination and implementation of the results of the Magpie Trial results by country group*
Barrier Number of countries from which at least one representative gave a response
Low and lower-middle 
income countries 
(n = 13#)
Upper-middle income 
countries 
(n = 3#)
High-income 
countries 
(n = 8#)
Total
Political barriers 8 2 2 12
Lack of information or awareness regarding 
magnesium sulphate
621 9
Costs of treatment 5 2 1 8
Lack of availability of personnel and hospitals 5 1 1 7
Lack of support from public authorities 4 1 2 7
Lack of availability of magnesium sulphate 5 0 1 6
Lack of clinical practice guidelines 1 1 3 5
Magnesium sulphate not registered for 
treatment of eclampsia/pre-eclampsia
110 2
* 17 respondents either did not reply or had illegible responses to this question.
# Total number of countries in this group.BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
Page 7 of 13
(page number not for citation purposes)
and high-income countries (median importance 1.0 and
1.0). Responsibility for payment for magnesium sulphate
and hospital care for pre-eclampsia varied across and
within countries and included governments, patients and
private insurance.
A range of professional and organisational actors was seen
to be influential in changing relevant policies related to
the use of magnesium sulphate (Table 4). A majority of
respondents from low and middle-incomes countries
considered central health authorities and hospital admin-
istrations to be influential. This contrasted with high-
income countries where these groups were less frequently
seen as having an important role in policy change. There
were important differences between low and lower-mid-
dle income countries and upper middle-income and high
income countries regarding the perceived influence of the
WHO, drug licensing agencies, the pharmaceutical indus-
try, politicians and patient organisations. Notably, only a
minority of respondents considered patient organisations
to be influential (18% overall).
Survey of drug information officers
Following repeated efforts, responses were obtained from
national drug information officers or drug regulatory offi-
cials for only nine of the twelve countries. Their responses
regarding the licensing, supply and distribution of magne-
sium sulphate are shown in Table 5. In contrast to the sur-
vey of Magpie collaborators, these respondents did not
report problems with licensing, supply or distribution in
their countries, and noted that magnesium sulphate was
on the essential medicines list for seven of the nine sam-
pled.
Obstetricians in five of these nine countries (Armenia,
India, Indonesia, the Philippines and South Africa) sug-
gested that magnesium sulphate was widely available and
widely used for both eclampsia and pre-eclampsia (Table
6). However, there was some uncertainty regarding the
importance of limitations to availability and differences
in availability across geographical areas and between pub-
lic and private hospitals.
No problems were reported by drug information officers
regarding the registration, supply or distribution of folic
acid in any of the nine countries, with the exception of
Bolivia. The same was true for ergometrin, with the excep-
tion of Cambodia, where frequent shortages were
reported due to its short shelf life. No problems were
reported for oxytocin (Table 7). This contrasts with mag-
nesium sulphate for which numerous problems with sup-
ply and distribution were noted.
For hydralazine, drug information officers in three coun-
tries reported that it was not licensed and in five countries
that there were problems with its supply. Problems with
the registration, supply and distribution of nevirapine
were reported in four of the nine countries, with Rwanda
the only country not reporting a problem with the supply
or distribution of this drug. Nevirapine is an expensive
drug compared to magnesium sulphate and indications
for its use vary across countries.
Given the difficulties in accessing appropriate respond-
ents for this study, and respondents' limited knowledge of
the information required by the questionnaire, we
decided that a larger survey of drug information officers in
low and lower-middle income countries would not likely
provide reliable and useful information.
Table 3: Facilitators to implementing the results of the Magpie Trial by country*
Facilitator Number of countries from which at least one representative gave a response
Low and lower-middle 
income countries 
(n = 13#)
Upper-middle income 
countries 
(n = 3#)
High-income 
countries 
(n = 8#)
Total
Channels to public authorities 6 2 2 10
Development/use of clinical practice 
guidelines
414 9
Publications in medical journals 5 0 2 7
R e s o u r c e s 411 6
International organisations 4 1 0 5
Professional organisations 2 3 3 8
Licensing and availability of magnesium 
sulphate
303 6
* 29 respondents provided illegible responses to this question.
# Total number of countries in this group.BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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Discussion
This multi-country study used a range of methods to
explore the wide variety of factors that hinder and facili-
tate the translation of research findings, in this case from
the Magpie Trial, into policies and practice across a range
of settings. It highlights two important issues: firstly, the
barriers to translating the findings of studies such as the
Magpie Trial into policy are complex, multifactoral and
context specific, as has been suggested elsewhere [2,11].
For example, if one considers barriers within the health
system, such as drug availability and licensing, this study
demonstrates that the availability of magnesium sulphate
remains an issue in some settings, although it was difficult
to ascertain the extent of this problem and there is likely
to be local variation. Furthermore, it proved difficult to
ascertain the number of countries in which magnesium
sulphate is not licensed for the treatment of eclampsia.
Even if the availability of magnesium sulphate was
assured, clinical practice guidelines and effective strategies
to implement these would still be needed to address bar-
riers at the practitioner level, and would need to be tai-
lored to particular settings. Although there is evidence
from some settings that practitioners may rapidly and
extensively change practice in response to new evidence
from RCTs and systematic reviews [30-33], this has not
been commonly demonstrated in resource poor settings.
This may reflect differences in facilitators of change
between low and high income settings, as discussed ear-
lier.
Another complex issue is that of interaction with and sup-
port from policy makers – the barrier most frequently
cited by respondents. Although we had not anticipated
this barrier, and had not asked about it in the closed-
ended questions, this finding mirrors that of a recent sys-
tematic review of the use of research in health policy-mak-
ing in which 'absence of personal contact' between
researchers and policy makers was identified as the most
common problem [5]. Although magnesium sulphate is
relatively inexpensive in terms of purchase price – less
than US$5 per patient [21] – political support and
national policies may be needed for a number of reasons.
These include registering the drug where it is not licensed,
ensuring that it is distributed and available in hospitals,
ensuring that health care professionals are appropriately
trained, and facilitating the access of women with pre-
eclampsia to hospital care. Given the complex nature of
the barriers to translating the Magpie Trial findings into
policy, the 'rational' model of the research-policy relation-
ship, in which new knowledge results in policy change,
therefore seems a less appropriate description of this
research translation process than the 'enlightenment'
model, which describes a more diffuse, non-linear rela-
tionship between research and policy and recognises that
Table 4: Organisations and individuals noted by respondents as having an important influence on changing policies related to the use of 
magnesium sulphate in their countries (%)
Organisation or individuals Low and lower-middle 
income countries
(n = 39#)
Upper-middle income 
countries
(n = 20#)
High-income 
countries
(n = 24#)
Medical or obstetrical association 92% 85% 88%
Hospital department of obstetrics 87% 85% 83%
Central health authorities 82% 70% 38%
Hospital administration 79% 60% 17%
World Health Organisation 79% 45% 8%
Nurse or midwife association 72% 35% 58%
Drug licensing agency 72% 10% 46%
Pharmaceutical industry 69% 25% 33%
Regional or local health authorities 67% 90% 33%
Mass media 56% 20% 46%
Individual influential professionals 51% 55% 75%
Politicians 51% 55% 8%
Public health insurance program 26% 65% 13%
Private health insurers 26% 35% 8%
Non-governmental organisations 26% 15% 4%
Other international organisations 26% 15% 4%
Other professional associations 21% 15% 17%
Patient organisations 13% 10% 33%
Others 13% 25% 21%
# Number of respondents.BMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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a single research study is unlikely to have a direct impact
on policy [10].
The second key finding is the difficulties experienced in
obtaining detailed information on drug availability and
use at country level. The pilot survey focused on low and
lower-middle income countries, where there appeared to
be both the greatest need and the largest problems. Infor-
mation was sought from the WHO's network of desig-
nated national drug information officers because we
believed they would be able to reliably answer questions
about the licensing, supply and distribution of magne-
sium sulphate. However, it was frequently difficult to con-
tact these officers. When they could be reached, they had
reliable but limited information about licensing, importa-
tion and local production, but no information on actual
use. Beyond this there were little, if any, reliable data from
WHO or other sources regarding the availability of mag-
nesium sulphate or other drugs at country level. This sug-
gests that a large investment of resources would be
required both to ascertain the magnitude and precise
nature of problems regarding the distribution and use of
magnesium sulphate internationally and to explore how
best to address these. The difficulties in obtaining infor-
mation, combined with the wide and differing range of
barriers between settings, makes it difficult to design any
single, widely generalisable intervention package that
might be used to promote the uptake of the Magpie Trial
findings into policy and practice across the study settings.
This is also likely to be the case for other drug and mater-
nal and child health interventions that research has
shown to be effective and that researchers and others wish
to translate into policy and practice.
This study has several limitations. Firstly, the findings
from the Magpie Trial Collaborative Group reflect the
nature of that group, comprised primarily of self-selected
obstetricians with a professional interest in pre-eclampsia.
However, there were several reasons why this study was
initiated with this Group, despite these limitations. It was
their concerns about failures to translate results from their
earlier trial [17] into practice in developing countries
[21,22] that prompted this study. They were therefore
motivated to participate in it. Furthermore, the Group had
expert knowledge of both the specific topic and obstetrical
care in their settings. Also, our survey of drug information
officers, conducted to complement the data provided by
the Group, demonstrates that it is difficult to access relia-
ble information, reflecting in part the paucity of rigorous
data regarding the availability and use of magnesium sul-
phate in low and middle-income countries. The data from
the Collaborative Group therefore provide useful insights
into the potential and limitations of senior researchers
across a wide range of countries to influence the transla-
tion of their findings into appropriate health care policies.
This study attempted a broad overview of research transla-
tion across a range of countries. This approach had the
advantage of allowing us to identify commonalities and
differences between countries, thereby improving the gen-
eralisability of the findings, but also limited the depth of
enquiry in any one setting. Although we have taken the
approach of grouping country findings using the World
Bank classification of level of income, we acknowledge
that this approach might mask differences both within
these groups and at sub-national levels. Further in-depth
studies, currently in progress, are exploring the use of
research evidence in policy making in several of the coun-
tries included in the Magpie Trial (G Woelk, personal
communication). These studies are exploring the view-
points of a wider group of policy actors, including senior
Table 5: Licensing, supply and distribution of magnesium sulphate as reported by drug information officers or drug regulatory officials 
– survey
Country Licensed for 
eclampsia
Licensed for 
pre-eclampsia
Imported or 
produced locally
Problems with 
supply or 
distribution
MgSO4 on EML Date included 
on EML
Armenia Yes Yes Imported No Yes 1994
Bolivia Yes Yes Both No Yes 1985
Cambodia Yes Yes Imported No Yes 2000
India NR NR Produced locally No No NA
Indonesia Yes Yes Produced locally No Yes 1983
Iran Yes Yes Produced locally No Yes 1981
Philippines Yes NR Produced locally No Yes 1989
Rwanda Yes Yes Both No Yes NR
Yemen Yes Yes Imported No No NA
MgSO4 = magnesium sulphate
EML = essential medicines list
NR = not reported
NA = not applicableBMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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policy makers within ministries and departments of
health and representatives of international organisations.
Conclusion
Despite robust evidence from a landmark trial and sys-
tematic review of the effectiveness of magnesium sulphate
for the treatment of pre-eclampsia, the drug is still not
available in some countries and its availability varies in
many others. Licensing, importation and production are
probably not the most important barriers in most settings
to translating this research evidence into practice. Rather,
a complex and multifaceted group of issues, differing
across contexts, inhibits the uptake into policy of research
findings on health issues such as the treatment of eclamp-
sia and pre-eclampsia [2]. The changes that are needed to
ensure widespread and equitable availability and use of
magnesium sulphate are therefore also variable and com-
plex. This helps to explain why publication of the findings
of important studies, such as the Magpie Trial, are impor-
tant but generally not sufficient to change policy and prac-
tice in the health services, particularly in low and middle
income countries. In the meantime, many women die
each year from complications of pregnancy associated
with pre-eclampsia [16]. What then can be done by
researchers and other actors and where does responsibility
lie?
Firstly, there is a need to identify credible national advo-
cates or "knowledge brokers"[4,6]. The Magpie Trial col-
laborators are willing advocates but frequently may not
have the contacts, skills or resources to influence relevant
policies [34]. Moreover, they only represent thirteen low
and lower-middle income countries. Secondly, once
appropriate advocates are identified, they may need help
in identifying the key target audiences for knowledge
transfer and in identifying channels to overcome political
barriers and influence those who are able to act [6]. In
some countries, policy actors such as the WHO, UNICEF
and other international agencies may play an important
role in opening doors to national level policy makers and
in promoting evidence-based policies and practice. Given
this influence, the WHO and other international agencies
should consider whether to raise the standards of evi-
dence that they use in their advisory work to national gov-
ernments and in their own choices of policy and
programme recommendations. Not all international
Table 6: Availability of magnesium sulphate and use for eclampsia and pre-eclampsia as reported by obstetricians – survey
Eclampsia Pre-eclampsia
Country Available
in hospitals
Geographic 
differences
 in availability
Public vs. 
Private
 hospitals
Used for
women with 
eclampsia
Reasons for 
MgSO4 not
 being used 
for all women
Used for 
women with
 pre-eclampsia?
Reasons for 
MgSO4 not
 being used 
for all women
Armenia
Obstetrician 1 All No No All All
Obstetrician 2 Most No No All All
Obstetrician 3 Most No No All All
India
Obstetrician 1 All No No All All
Obstetrician 2 Some Yes No Most Few D, E
Obstetrician 3 Some Yes No Some A Some E
Obstetrician 4 Some Yes No Most Some D, E
Indonesia
Obstetrician 1 Most Yes No Most A, B, C Most D, E
Obstetrician 2 Some Yes Yes Most A Most D, E
Philippines
Obstetrician 1 Most Yes Yes All All
Obstetrician 2 All Don't know Don't know All All
South Africa
Obstetrician 1 All No No All Most
Obstetrician 2 All No No All Some F
A = Problems with availability
B = Different drug used
C = Lack of awareness among clinicians
D = Lack of awareness among clinicians
E = Problems with availability
F = Not a priority
MgSO4 = magnesium sulphateBMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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Table 7: Licensing, supply and distribution of five other obstetrical drugs as reported by drug information officers or drug regulatory 
officials – survey
Country/drug Licensed Problems with 
supply or 
distribution
Comments
Armenia
Folic acid Yes No
Ergometrin Yes No The registered form is methylergometrine.
Oxytocin Yes No
Hydralazine No Yes There is a demand for the drug, but no interest from drug 
companies.
Nevirapine Yes Yes There is a demand for the drug, but no interest from drug 
companies.
Bolivia
Folic acid Yes & No Yes Availability problems within the public health services (logistical).
Ergometrin No No
Oxytocin No No
Hydralazine No Yes Not available in the national market. Only imported by two 
suppliers for use in public health facilities.
Nevirapine Yes Yes Not on national EML & not registered so not available on the 
national market. AZT is available but expensive.
Cambodia
Folic acid Yes No
Ergometrin Yes Yes There are often shortages due to short shelf-life.
Oxytocin Yes No
Hydralazine Yes Yes There are often shortages due to short shelf-life.
Nevirapine No DN Not available in Cambodia.
India
Folic acid NR No
Ergometrin NR No
Oxytocin NR No
Hydralazine NR Yes Low demand as a better therapeutic alternative is available. 
Produced by one manufacturer only.
Nevirapine NR Yes & No
Indonesia
Folic acid No No
Ergometrin No No
Oxytocin No No
Hydralazine No No
Nevarapine DN DN Only been registered in 2002 so too early to know if there are any 
problems with supply.
Iran
Folic acid Yes No
Ergometrin Yes No
Oxytocin Yes No
Hydralazine Yes No
Nevirapine No Yes This drug is not being used in Iran.
Philippines
Folic acid Yes No
Ergometrin Yes No
Oxytocin Yes No
Hydralazine Yes No
Nevirapine No NR Not registered by the Bureau of Food & Drugs.
Rwanda
Folic acid Yes No
Ergometrin DN No
Oxytocin Yes No
Hydralazine Yes Yes Many health facilities of out of stock.
Nevirapine Yes No
Yemen
Folic acid Yes DN
Ergometrin Yes DNBMC Health Services Research 2005, 5:68 http://www.biomedcentral.com/1472-6963/5/68
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Oxytocin Yes DN
Hydralazine DN DN
Nevirapine DN DN No cases.
DN = do not know
NR = not reported
Table 7: Licensing, supply and distribution of five other obstetrical drugs as reported by drug information officers or drug regulatory 
officials – survey (Continued)
agencies, however, see themselves as having an advocacy
role in changing clinical practice. For example, efforts
made by the Magpie Trial investigators and others to per-
suade the President of the International Federation of
Obstetricians and Gynaecologists that he and the organi-
sation had potentially important roles in promoting the
uptake of magnesium sulphate met with reluctance for
himself or his organisation to interfere in the clinical free-
dom of individual clinicians (Chalmers, personal com-
munication 2005) [21].
Our findings highlight the importance placed by respond-
ents on interactions between policy makers, researchers
and other stakeholders in facilitating the uptake of
research findings into policies. Other studies examining
the process of transferring research findings to key policy
actors have also suggested that this process should be
interactive in order to maximise its effectiveness [6]. These
interactions can be initiated by individual researchers or
policy makers but systems level mechanisms, such as
observatories that bring together the producers and users
of research, may also be useful [3,4,34,35] and should be
considered for low and middle income countries, as part
of strengthening national health research systems [1]. The
sharing of experiences between such units needs to be
encouraged so as to identify generalisable lessons for
research translation. Financial support to ensure that mag-
nesium sulphate is licensed and imported or produced
locally may also be necessary. Moreover, financial support
may be important to eliminate out of pocket payments
that are acting as barriers in some settings to accessing
essential medical care such as magnesium sulphate for
eclampsia and severe pre-eclampsia.
At the implementation level, training health care profes-
sionals in developing countries to provide appropriate
care presents challenges that are similar to those encoun-
tered in high-income countries [36-38]. These challenges
are even more important to address in low-income coun-
tries because of the more severe consequences of not
doing so and a greater need to use scarce resources effi-
ciently. Evidence-based, international guidelines that can
be locally adapted, such as those provided in the WHO
Reproductive Health Library [39], could provide a valua-
ble basis for both developing and implementing appro-
priate national clinical policies and practice guidelines.
Other interventions to improve the use of medicines in
developing countries have been outlined elsewhere [40],
and may assist in addressing delays in responding to new
evidence on the effectiveness of drugs.
More broadly, it would seem sensible to organise a wide
programme of support rather than multiple one-off
efforts for essential medicines in maternal and child
health. Such a programme could provide an ongoing
framework and support for ensuring that important
research findings, such as those of the Magpie Trial, are
translated into appropriate policies and practice.
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